Bicalutamide-d5

• UNSPSC Description:

  Bicalutamide-d5 is deuterated labeled Bicalutamide (HY-14249). Bicalutamide is an orally active non-steroidal androgen receptor (AR) antagonist. Bicalutamide can be used for the research of prostate cancer[1].

• Target Antigen:

  Androgen Receptor; Autophagy; Isotope-Labeled Compounds

• Type:

  Isotope-Labeled Compounds

• Related Pathways:

  Autophagy;Others;Vitamin D Related/Nuclear Receptor

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Solubility:

  10 mM in DMSO

• Smiles:

  FC1=CC=C(S(=O)(C([2H])([2H])[C@@](O)(C([2H])([2H])[2H])C(NC2=CC=C(C#N)C(C(F)(F)F)=C2)=O)=O)C=C1

• Molecular Weight:

  435.40

• References & Citations:

  [1]Nicola J. Clegg,1 John Wongvipat,1,2 Jim Joseph, ARN-509: a novel anti-androgen for prostate cancer treatment. Cancer Res. 2012 March 15; 72(6): 1494-1503.|[2]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported